- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00002705
Topotecan in Treating Children With Refractory Leukemia
TOPOTECAN FOR CHILDREN WITH REFRACTORY LEUKEMIA, A PEDIATRIC ONCOLOGY GROUP PHASE I COOPERATIVE AGREEMENT STUDY
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
I. Describe the qualitative and quantitative toxic effects, including acute and chronic dose-limiting toxicity, cumulative toxicity, and time to recovery, in pediatric patients with refractory leukemia who are treated with a 30-minute daily infusion of topotecan (TOPO) for up to 12 consecutive days every 3 weeks.
II. Estimate the maximum tolerated dose of TOPO that results in tolerable, predictable, and reversible toxicity.
III. Determine the precautions and supportive therapy that should be used and the clinical and laboratory studies needed to monitor or alter therapy to prevent unacceptable toxicity in these patients.
IV. Observe any antileukemic effects that may occur during this phase I study in which duration of treatment is increased from 7 to 9 and then 12 days and TOPO doses are escalated.
V. Determine the recommended phase II pediatric dose of TOPO. VI. Characterize the pharmacokinetic parameters of TOPO and evaluate changes in these parameters with the first and last doses to determine whether there is drug accumulation.
VII. Correlate, if possible, these pharmacokinetic parameters with clinical response and toxicity.
OUTLINE:
Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Montreal Children's Hospital
-
Montreal, Quebec, Canada, H3T 1C5
- Hopital Sainte Justine
-
-
-
-
-
San Juan, Porto Rico, 00936-5067
- University of Puerto Rico School of Medicine Medical Sciences Campus
-
-
-
-
-
Geneva, Suisse, 1211
- Clinique de Pediatrie
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama Comprehensive Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
La Jolla, California, États-Unis, 92093-0658
- University of California San Diego Cancer Center
-
Palo Alto, California, États-Unis, 94304
- Lucile Packard Children's Hospital at Stanford
-
-
Florida
-
Gainesville, Florida, États-Unis, 32610-100277
- Shands Hospital and Clinics, University of Florida
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory University Hospital - Atlanta
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60614
- Children's Memorial Hospital, Chicago
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160-7357
- University of Kansas Medical Center
-
Wichita, Kansas, États-Unis, 67214
- Via Christi Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70112
- MBCCOP - LSU Medical Center
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, États-Unis, 02111
- Boston Floating Hospital Infants and Children
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Children's Hospital of Michigan
-
-
Missouri
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, États-Unis, 14263-0001
- Roswell Park Cancer Institute
-
Syracuse, New York, États-Unis, 13210
- State University of New York - Upstate Medical University
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 28801
- Memorial Mission Hospital
-
Durham, North Carolina, États-Unis, 27710
- Duke Comprehensive Cancer Center
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38105-2794
- Saint Jude Children's Research Hospital
-
-
Texas
-
Dallas, Texas, États-Unis, 75230
- Medical City Dallas Hospital
-
Dallas, Texas, États-Unis, 75235-9154
- Simmons Cancer Center - Dallas
-
Houston, Texas, États-Unis, 77030
- Baylor College of Medicine
-
Lackland Air Force Base, Texas, États-Unis, 78236-5300
- San Antonio Military Pediatric Cancer and Blood Disorders Center
-
San Antonio, Texas, États-Unis, 78284-7811
- University of Texas Health Science Center at San Antonio
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Midwest Children's Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
-Histologically or cytologically confirmed leukemia refractory to conventional therapy or for which no effective curative therapy exists
PATIENT CHARACTERISTICS:
- Age: Under 21
- Performance status: ECOG 0-2
- Life expectancy: At least 8 weeks
- Adequate platelet count and hemoglobin required (transfusion allowed)
- Bilirubin no greater than 1.5 mg/dL
- AST or ALT no greater than 2 times normal
- Creatinine less than 1.5 mg/dL
- Adequate nutritional status, e.g. higher than third percentile weight for height
- Albumin at least 3 g/dL
- No severe uncontrolled infection
- No pregnant women
- Effective contraception required of fertile women
PRIOR CONCURRENT THERAPY:
- At least 3 weeks since systemic chemotherapy (6 weeks since nitrosoureas)
- Recovered at least 3 months since bone marrow transplant (at least 6 months since total-body irradiation)
- No concurrent anticancer therapy
- No concurrent treatment studies
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Arm I
Single-Agent Chemotherapy.
Topotecan, TOPO, NSC-609699.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Wayne Lee Furman, MD, St. Jude Children's Research Hospital
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NCI-2012-01833
- POG-9575
- CDR0000064511 (Identificateur de registre: PDQ (Physician Data Query))
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Leucémie
-
Shenzhen Second People's HospitalRecrutementLeucémie | Myéloïde | Chronique | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | PositifChine
Essais cliniques sur chlorhydrate de topotécan
-
Centre Francois BaclesseGlaxoSmithKline; Centre d'Etudes et de Recherche pour l'Intensification du...RésiliéCancer | Chimiothérapie | Rechute | OvaireFrance